We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Adds Fourth Indian Site to Ranbaxy’s Consent Decree
FDA Adds Fourth Indian Site to Ranbaxy’s Consent Decree
October 7, 2013
In an enforcement action industry experts say signals FDA doubts about the generic giant’s culture of quality, the agency last month added Ranbaxy’s Mohali, India, facility to a consent decree it signed in January 2012 and issued an import alert on the plant, which makes oral solids.